Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI

STEMI Clinical Trial

Official title:

Effect of Covid-19 Epidemic on Primary PCI and Prognosis in Patients With Acute STEMI

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04427735
• Other study ID #: BFH-COVID-19 and Primary PCI
• Status: Recruiting
• Start date: January 24, 2019
• Est. completion date: July 24, 2021

Study information

• Verified date: June 2020
• Source: Beijing Friendship Hospital
• Contact: Hongwei Li, doctor
• Phone: 0086 10 63139780
• Email: lhw19656[@]sina.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. It is necessary to study the treatment of STEMI patients in the real world under the influence of the epidemic,which provide effective suggestions and strategies for emergency and severe treatment.

Description:

The epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. The patients' prognosis is poor because the epidemic situation runs on medical resources, delays the diagnosis and treatment of other diseases such as cardiovascular diseases, and the patients' willingness to see a doctor is reduced. In particular, the delay in the treatment of STEMI, which needs PCI treatment, will cause more damage to the patients. It is necessary to study the treatment of STEMI patients in the real world under the influence of the epidemic. In this study, STEMI patients who experienced emergency PCI treatment after the covid-19 outbreak in 2020 were included, and compared with the data of the same period in 2019,we will analyze the pre hospital treatment time, vascular opening time,and the major cardiovascular adverse events, which provide effective suggestions and strategies for emergency and severe treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 24, 2021
• Est. primary completion date: July 24, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Continuous inclusion of patients with definite diagnosis of acute ST segment elevation myocardial infarction and emergency PCI intervention.

Exclusion Criteria:

• Febrile patients, patients with severe infection,

• ST segment elevation myocardial infarction during hospitalization,

• Patients who could not cooperate with each other.

Related Conditions & MeSH terms

• ST Elevation Myocardial Infarction
• STEMI

Locations

Country	Name	City	State
China	Beijing Friendship Hospital, Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MACE (major adverse cardiovascular events)	cardiovascular death, re-infarction, malignant arrhythmia,heart failure, revascularization, and stroke	1 year
Primary	all-cause death	death caused by all reason	1 year